SLC5A2 and atherosclerosis: A meta-analysis of 6 placebo-controlled clinical outcomes trials (EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, CREDENCE, VERTIS CV) (85, 86, 92, 93), including a total of 46 969 patients (66.2% with prevalent ASCVD) suggests that SGLT2 inhibitors significantly reduced the risk of MACE (HR, 0.90; 95% CI, 0.85–0.95;); the presence or absence of ASCVD did not modify the treatment outcome on MACE (HR, 0.89; 95% CI, 0.83–1.07) (94).